Research progress on the mechanism of acquired drug resistance of epi-dermal growth factor receptor tyrosine kinase inhibitor and reversal in traditional Chinese medicine

JIA Chunxin,ZHANG Xin,MOU Ruiyu,JIA Yingjie
DOI: https://doi.org/10.20047/j.issn1673-7210.2023.32.12
2023-01-01
Abstract:Non-small cell lung cancer is one of the most common subtypes of lung cancer,and epidermal growth factor receptor mutations are key factor in its pathogenesis.Epidermal growth factor receptor tyrosine kinase inhibitor such as Erlotinib and Gefitinib provide more effective treatment for cancer patients.However,during treatment with epidermal growth factor receptor tyrosine kinase inhibitor,tumour cell develop resistance through mutations,activation of bypass or downstream signalling pathways,and changes in the levels of inflammatory factor and immune cell in the tumour microenvironment,limiting their long-term efficacy.Previous clinical and experimental studies have suggested that some monomers and compounds of traditional Chinese medicine can enhance body's immune response to tumours by inhibiting multiple signalling pathways related to epidermal growth factor receptor and modulating the tumour microenvironment,thereby effectively inhibiting the progression of epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.This article reviews the reversal of acquired epidermal growth factor receptor tyrosine kinase inhibitor drug resistance in traditional Chinese medicine.
What problem does this paper attempt to address?